Literature DB >> 8110879

Capillary leak syndrome associated with elevated IL-2 serum levels after allogeneic bone marrow transplantation.

I Funke1, O Prümmer, H Schrezenmeier, D Hardt, M Weiss, F Porzsolt, R Arnold, H Heimpel.   

Abstract

The pathophysiological mechanisms involved in the development of a spontaneous systemic capillary leak syndrome (CLS) are unknown. In contrast, CLS is a well-known side effect of high-dose interleukin-2 (IL-2) therapy in solid tumors. We report on a patient who developed CLS with high serum levels of endogenous IL-2 under immunosuppressive therapy for chronic graft-versus-host disease (GvHD) after allogeneic bone marrow transplantation (BMT). Generalized edema persisted for 10 weeks. The condition resolved after antibiotic therapy of a septic shock with beta hemolyzing streptococci group A. Thus, a latent infection may alter cytokine homeostasis and may cause CLS in BMT patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8110879     DOI: 10.1007/bf01695920

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  23 in total

1.  High urinary leukotriene E4 (LTE4) and thromboxane 2 (TXB2) levels are associated with capillary leak syndrome in bone marrow transplant patients.

Authors:  R A Cahill; Y Zhao; R Murphy; A Sala; M Foegh; T Spitzer; H J Deeg
Journal:  Adv Prostaglandin Thromboxane Leukot Res       Date:  1991

2.  Interleukin-1 induces interleukin-6 production in peripheral blood monocytes.

Authors:  G Tosato; K D Jones
Journal:  Blood       Date:  1990-03-15       Impact factor: 22.113

3.  Differential regulation of lipopolysaccharide-induced interleukin 1 and tumor necrosis factor synthesis: effects of endogenous and exogenous glucocorticoids and the role of the pituitary-adrenal axis.

Authors:  S H Zuckerman; J Shellhaas; L D Butler
Journal:  Eur J Immunol       Date:  1989-02       Impact factor: 5.532

4.  Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes.

Authors:  L A Cone; D R Woodard; P M Schlievert; G S Tomory
Journal:  N Engl J Med       Date:  1987-07-16       Impact factor: 91.245

5.  Pathogenesis of the toxic shock syndrome: T cell mediated lethal shock caused by the superantigen TSST-1.

Authors:  T Miethke; K Duschek; C Wahl; K Heeg; H Wagner
Journal:  Eur J Immunol       Date:  1993-07       Impact factor: 5.532

6.  Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2.

Authors:  M Rosenstein; S E Ettinghausen; S A Rosenberg
Journal:  J Immunol       Date:  1986-09-01       Impact factor: 5.422

7.  Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids.

Authors:  J T Vetto; M Z Papa; M T Lotze; A E Chang; S A Rosenberg
Journal:  J Clin Oncol       Date:  1987-03       Impact factor: 44.544

8.  [Hypovolaemic shock due to increased capillary permeability (author's transl)].

Authors:  P Maestracci; P Benoit; J Dupeyrat; R Maiolini
Journal:  Nouv Presse Med       Date:  1981-02-07

9.  IL-2-activated human killer lymphocytes but not their secreted products mediate increase in albumin flux across cultured endothelial monolayers. Implications for vascular leak syndrome.

Authors:  N K Damle; L V Doyle
Journal:  J Immunol       Date:  1989-04-15       Impact factor: 5.422

10.  The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome.

Authors:  A Waage; P Brandtzaeg; A Halstensen; P Kierulf; T Espevik
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

View more
  1 in total

1.  Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours.

Authors:  Mira M Shenouda; Amy Gillgrass; Tina Nham; Richard Hogg; Amanda J Lee; Marianne V Chew; Mahsa Shafaei; Craig Aarts; Dean A Lee; John Hassell; Anita Bane; Sukhbinder Dhesy-Thind; Ali A Ashkar
Journal:  Breast Cancer Res       Date:  2017-07-01       Impact factor: 6.466

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.